As assessed by phospho-Akt immunostaining, we detected a dramatic decrease by 70%, 78% and 62%, respectively, in p-Akt levels in RIP-Tag2 and colon and pancreatic tumor xenografts, compared with vehicle-treated animals (Figures 6C–F). This evidence concerns the gene AKT1 and pancreatic neoplasm.